{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:40:34Z","timestamp":1794490834639,"version":"4.9.1"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["HEALTH-F2-2010-242114"],"award-info":[{"award-number":["HEALTH-F2-2010-242114"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["NCT01248195"],"award-info":[{"award-number":["NCT01248195"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.euroneuro.2020.01.007","type":"journal-article","created":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T08:20:00Z","timestamp":1580977200000},"page":"131-135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Duration of untreated psychosis and response to treatment: an analysis of response in the OPTiMiSE cohort"],"prefix":"10.1016","volume":"32","author":[{"given":"Linda","family":"Levi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mor","family":"Bar Haim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimon","family":"Burshtein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"Winter-Van Rossum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Heres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5263-8888","authenticated-orcid":false,"given":"Geva","family":"Shenkman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9 S.","family":"Kahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Weiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2020.01.007_bib0001","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1176\/appi.ps.201400124","article-title":"Duration of untreated psychosis in community treatment settings in the United States","volume":"66","author":"Addington","year":"2015","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.euroneuro.2020.01.007_bib0002","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","article-title":"Remission in schizophrenia: proposed criteria and rationale for consensus","volume":"162","author":"Andreasen","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.01.007_bib0003","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.schres.2012.08.017","article-title":"Duration of untreated psychosis and negative symptoms\u2014a systematic review and meta-analysis of individual patient data","volume":"142","author":"Boonstra","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2020.01.007_bib0004","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0166-2236(82)90202-8","article-title":"Two syndromes in schizophrenia?","volume":"5","author":"Crow","year":"1982","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.euroneuro.2020.01.007_bib0005","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1192\/bjp.177.6.511","article-title":"Causes and consequences of duration of untreated psychosis in schizophrenia","volume":"177","author":"Drake","year":"2000","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.01.007_bib0006","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.euroneuro.2012.04.019","article-title":"Persistent negative symptoms in first episode patients with schizophrenia: results from the European first episode schizophrenia trial","volume":"23","author":"Galderisi","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2020.01.007_bib0007","doi-asserted-by":"crossref","unstructured":"Guy, W., 1976. Clinical global impressions scale. ECDEU assessment manual for psychopharmacology, 217\u2013222.","DOI":"10.1037\/e591322011-001"},{"key":"10.1016\/j.euroneuro.2020.01.007_bib0008","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1176\/appi.ajp.2011.11030459","article-title":"Long-term follow-up of the TIPS early detection in psychosis study: effects on 10-year outcome","volume":"169","author":"Hegelstad","year":"2012","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.01.007_bib0009","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S2215-0366(18)30252-9","article-title":"Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study","volume":"5","author":"Kahn","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.01.007_bib0010","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1176\/appi.ajp.2015.15050632","article-title":"Comprehensive versus usual community care for first-episode psychosis: 2-year outcomes from the NIMH raise early treatment program","volume":"173","author":"Kane","year":"2015","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.01.007_bib0011","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2020.01.007_bib0012","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/eip.12217","article-title":"Duration of active psychosis and first\u2010episode psychosis negative symptoms","volume":"11","author":"Lyne","year":"2017","journal-title":"Early Interv. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.01.007_bib0013","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.v58n1205","article-title":"The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials","author":"Marder","year":"1997","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.01.007_bib0014","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1001\/archpsyc.62.9.975","article-title":"Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review","volume":"62","author":"Marshall","year":"2005","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.01.007_bib0015","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.schres.2012.06.013","article-title":"Reliability and validity of the personal and social performance scale in patients with schizophrenia","volume":"140","author":"Nafees","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2020.01.007_bib0016","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.schres.2014.10.039","article-title":"The efficacy of targeted health agents education to reduce the duration of untreated psychosis in a rural population","volume":"161","author":"Padilla","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2020.01.007_bib0017","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1192\/bjp.bp.113.127753","article-title":"Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis","volume":"205","author":"Penttil\u00e4","year":"2014","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.01.007_bib0018","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1176\/appi.ajp.162.10.1785","article-title":"Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis","volume":"162","author":"Perkins","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.01.007_bib0019","article-title":"The mini-international neuropsychiatric interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","author":"Sheehan","year":"1998","journal-title":"J. Clin. Psychiatry"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X20300237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X20300237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T01:29:04Z","timestamp":1778549344000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X20300237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":19,"alternative-id":["S0924977X20300237"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2020.01.007","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Duration of untreated psychosis and response to treatment: an analysis of response in the OPTiMiSE cohort","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2020.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}